The training cohort consisted of 141 samples which were obtained as 100-150bp amplicons with 5' adapters (see S3 Table) . Amplicons were generated 1 9 0 using the high fidelity Pfu-based Herculase II Fusion DNA polymerase (Agilent, 1 9 1 Santa Clara, CA, USA) at 35 PCR cycles following the manufacturer's master mix 1 9 2 and PCR cycling condition recommendation recommended by the manufacturer. Amplicons were quantified using Qiagen QIAxcel (Qiagen, Manchester UK.), 1 9 6 then pooled at roughly equimolar concentrations. Agencourt AMPure XP beads against each other for thresholds between 0 and 1. The resulting curve represents between MSI-H and MSS samples. The classifier was designed to include information both on changes in MNR assay. Assuming that, for a given mismatch repair status, mutations at the different 2 5 4 markers occur independently from each other, then: assuming that in such cases there is insufficient evidence for an MNR mutation and 2 7 4 therefore bias is not meaningful. The results are presented as a score
Here we used a set of samples to determine, for each MNR, the following 2 7 7 parameters used in the classification: (1) A threshold for the frequency of reads showing a deletion (for the choice of thresholds see previous paragraph and the showing a deletion and significant allelic imbalance and; (5) The proportion of MSS These parameters were then used to calculate the score for each tumour in a 2 8 7 second, independent set of samples. Samples with a score below 0 were classified 2 8 8
as MSS and those above as MSI-H. (dbSNP137) with a minor allele frequency larger than 20% within 30bp of the repeat. if the probability of observing a minor allele in at least one SNP was above 20%, MNRs. From these 562 markers, MNRs within repetitive elements and regions of low complexity (likely to be refractory to amplicon design) were also excluded, producing 3 1 1 a final list of 120 MNRs (S2 Table) . To eliminate potentially uninformative repeats, amplicons were designed for 3 1 3 all 120 MNRs. These were initially tested in FFPE samples from the discovery for the longer repeat shown, reads representing deletions of more than one base pair 3 3 0 are also observed in the MSS sample, while a second peak can be observed To illustrate levels of allelic variation observed, results from a single MNR [39]) were also added to the analysis at this stage. These 43 MNRs were each typed 3 5 0 in a minimum of 28 MSI-H and 30 MSS tumours in the discovery cohort, and ROC 3 5 1 curves were generated to assess the ability of each to discriminate between MSI-H and below each threshold as MSS (S2 Table) . The AUC for LR46 was 0.83 (95% confidence interval 0.71-0.84) and 0.99 (0.98- repeats were selected and together with the two poly-C MNR with the largest AUC formed our final panel (S3 Table) . As described in the Methods section, the primers 3 6 2 for this panel were redesigned to produce shorter amplicons (S3 Table) . To establish the parameters required by the classification procedure, the were used to establish thresholds for each marker and to estimate the probabilities which data were available for this marker, but only in 4 of the 72 MSS samples. Of the 139 samples depicted in Fig 4A, 60 samples The method presented here allows sequence-based discrimination between promising markers, and two rounds of amplicon assessment. Although, this does not 4 5 0 ensure that the optimal set of MNRs was identified, the performance of the panel is 4 5 1 comparable to that of fragment analysis.
5 2
We chose relatively short MNRs for our test to diminish the probability of PCR MNR length, a potential confounding factor in cases where no normal material is 4 5 5 available. However, somatic instability is also lower meaning that genuine mutations 4 5 6 will tend to affect only one allele. Therefore, even allowing for PCR errors, mutant 4 5 7 reads should concentrate on one allele. We showed that this can be assessed using allele is likely to be affected in a different proportion of cells in a sample since, during 4 6 1 clonal evolution, there will be a time interval between the occurrence of the two 4 6 2 mutations, and this time interval is expected to be larger for shorter microsatellites. To our knowledge, this is the first method for assessing MSI that uses allelic information. Although we only use allelic data to assess bias in the distribution of 4 6 5 mutant reads, it can also help to distinguish between somatic and germline variation, in particular in situations where no normal material is available, but the tumour is can be excluded from the analysis although it would also be possible to treat each 4 6 9 allele separately. Allelic analysis, however, is only possible for MNRs heterozygous 4 7 0 for flanking SNPs in a particular sample. In principle, it would be feasible to restrict 4 7 1 the score calculation to such MNRs. However, such a procedure would disregard 4 7 2 information from many of the amplicons used, and require larger marker panels, 4 7 3 increasing assay costs. Here we used thresholds on the frequency of reads representing mutated 4 7 5
MNRs because we wanted to dichotomise the data. Other approaches would be 4 7 6 possible, however, using a threshold that is above the frequency observed in the 4 7 7 majority of the MSS samples is consistent with the approaches followed by other Since our test aims to detect MSI-H tumours, it seems reasonable to use 4 8 5 fragment analysis as the reference technique. However, MSI detection is usually a 4 8 6 means for assessing MMR proficiency. It is noteworthy that in 3 out of 4 cases where 4 8 7 there were discrepancies between our results and the results from fragment 4 8 8 analysis, there were also discrepancies between fragment analysis and IHC results. In summary, we propose an approach to the detection of MSI-H tumours 4 9 0 whose main advantage is its simplicity, making it suitable for high throughput where there is a germline molecular defect. Expansion of testing to all colorectal 4 9 5 cancers has been shown to be cost effective in the UK [40] and is soon to become will have clinical utility while modest costs and the ability to link this analysis to 5 0 0 routine pathology assessment with help to ensure rapid adoption and facilitate 5 0 1 further molecular approaches to tumour profiling and precision medical care. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): 13. Julie C, Tresallet C, Brouquet A, Vallot C, Zimmermann U, Mitry E, et al.
